Paul T Kotzbauer Selected Research

Dementia (Dementias)

1/2022	Proteinopathy and Longitudinal Cognitive Decline in Parkinson Disease.
1/2020	APOE genotype regulates pathology and disease progression in synucleinopathy.
10/2015	Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease.
6/2015	CSF proteins and resting-state functional connectivity in Parkinson disease.
2/2014	A quantitative study of α-synuclein pathology in fifteen cases of dementia associated with Parkinson disease.
10/2012	Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul T Kotzbauer Research Topics

Disease

22	Parkinson Disease (Parkinson's Disease) 03/2024 - 06/2004
7	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2019 - 04/2003
6	Dementia (Dementias) 01/2022 - 10/2012
5	Lewy Body Disease (Lewy Body Dementia) 03/2024 - 01/2022
4	Multiple System Atrophy 12/2023 - 01/2019
4	Alzheimer Disease (Alzheimer's Disease) 01/2023 - 11/2016
4	Disease Progression 01/2020 - 01/2013
3	Synucleinopathies 01/2023 - 10/2012
3	Cognitive Dysfunction 01/2022 - 10/2012
3	Parkinsonian Disorders (Parkinsonism) 01/2021 - 06/2004
1	Atrophy 01/2021
1	Corticobasal Degeneration 01/2021
1	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 01/2021
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2019
1	Frontotemporal Dementia (Semantic Dementia) 01/2019
1	Amyloid Plaque 11/2016
1	Pathologic Processes 08/2013
1	Tauopathies 10/2012
1	Dystonia (Limb Dystonia) 09/2010
1	Sarcoma (Soft Tissue Sarcoma) 05/2010
1	Neuroinflammatory Diseases 07/2008
1	Inflammation (Inflammations) 07/2008
1	Neuroaxonal Dystrophies (Neuroaxonal Dystrophy, Late Infantile) 02/2008
1	Tremor (Tremors) 05/2006
1	Neurodegeneration with brain iron accumulation (NBIA) 01/2005
1	Pantothenate Kinase-Associated Neurodegeneration (Hallervorden-Spatz Disease) 01/2005

Drug/Important Bio-Agent (IBA)

15	SynucleinsIBA 12/2023 - 08/2012
11	Proteins (Proteins, Gene)FDA Link 12/2023 - 10/2012
9	alpha-SynucleinIBA 03/2024 - 04/2003
5	Amyloid (Amyloid Fibrils)IBA 01/2022 - 04/2003
2	Apolipoproteins E (ApoE)IBA 01/2022 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 11/2016
2	PrionsIBA 01/2019 - 08/2013
2	IronIBA 02/2008 - 05/2006
2	pantothenate kinaseIBA 05/2006 - 01/2005
1	Amyloid beta-PeptidesIBA 01/2023
1	Indicators and Reagents (Reagents)IBA 01/2021
1	Levodopa (L Dopa)FDA LinkGeneric 01/2021
1	ApolipoproteinsIBA 01/2020
1	DNA-Binding Proteins (DNA Binding Protein)IBA 01/2019
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2019
1	Carbon-11IBA 01/2018
1	Fluorine-18IBA 01/2018
1	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 06/2015
1	Prion ProteinsIBA 08/2013
1	Protein AggregatesIBA 08/2013
1	Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)IBA 08/2013
1	LigandsIBA 01/2013
1	LysophospholipidsIBA 09/2010
1	Phospholipids (Phosphatides)FDA LinkGeneric 09/2010
1	Phosphoglycerate Kinase (Kinase, Phosphoglycerate)IBA 05/2010
1	Ubiquitin CIBA 05/2010
1	Superoxides (Superoxide)IBA 07/2008
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 07/2008
1	Calcium-Independent Phospholipases A2IBA 02/2008
1	Ubiquitinated ProteinsIBA 02/2008
1	Amyloidogenic ProteinsIBA 06/2004

Therapy/Procedure

2	Therapeutics 01/2021 - 07/2008